BioCentury | Feb 16, 2015
Company News

J&J, Valneva deal

Valneva purchased Crucell Sweden AB from Johnson & Johnson’s Janssen’s Crucell Holland B.V. for EUR45 million ($51 million). The deal includes the vaccine Dukoral , which prevents cholera and traveler’s diarrhea caused by enterotoxigenic Escherichia coli...
BioCentury | Dec 22, 2014
Clinical News

cAd3-EBO Z: Phase I started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z...
BioCentury | Dec 22, 2014
Clinical News

MVA-BN Filo: Phase I started

Bavarian Nordic said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z from GlaxoSmithKline plc (LSE:GSK;...
BioCentury | Oct 27, 2014
Company News

Bavarian Nordic, J&J deal

Bavarian Nordic granted the Johnson & Johnson's Crucell Holland B.V. exclusive, worldwide rights to Ebola vaccine MVA-BN Filo . Bavarian Nordic will receive an upfront payment of $25 million and is eligible to up to $20...
BioCentury | Oct 23, 2014
Company News

Bavarian Nordic gains on J&J Ebola deal

Bavarian Nordic A/S (CSE:BAVA) gained DKK36.50 (24%) to DKK186.50 after the Crucell Holland B.V. unit of Johnson & Johnson (NYSE:JNJ) paid $25 million up front to license exclusive, worldwide rights to Ebola vaccine MVA-BN Filo...
BioCentury | Oct 7, 2013
Company News

CureVac, J&J deal

Johnson & Johnson's Crucell Holland B.V. partnered with CureVac to develop an influenza vaccine. The flu vaccine will use J&J's antigen sequences and CureVac's RNActive technology, which includes optimizing mRNA base-pair content, engineering untranslated regions...
BioCentury | Jan 7, 2013
Company News

GlycoVaxyn, J&J deal

GlycoVaxyn and the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson will use GlycoVaxyn's bio-conjugation technology to develop a multivalent bacterial vaccine. Under the three-year deal, GlycoVaxyn and Janssen's Crucell Holland B.V. affiliate will collaborate...
BioCentury | Jan 5, 2013
Company News

GlycoVaxyn, Janssen in vaccine deal

...bio-conjugation technology to develop a multivalent bacterial vaccine. Under the three-year deal, GlycoVaxyn and Janssen's Crucell Holland BV...
Items per page:
1 - 8 of 8
BioCentury | Feb 16, 2015
Company News

J&J, Valneva deal

Valneva purchased Crucell Sweden AB from Johnson & Johnson’s Janssen’s Crucell Holland B.V. for EUR45 million ($51 million). The deal includes the vaccine Dukoral , which prevents cholera and traveler’s diarrhea caused by enterotoxigenic Escherichia coli...
BioCentury | Dec 22, 2014
Clinical News

cAd3-EBO Z: Phase I started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z...
BioCentury | Dec 22, 2014
Clinical News

MVA-BN Filo: Phase I started

Bavarian Nordic said the University of Oxford began an open-label, dose-escalation, U.K. Phase I trial to evaluate 2 doses of the company’s MVA-BN Filo and 3 doses of intramuscular cAd3-EBO Z from GlaxoSmithKline plc (LSE:GSK;...
BioCentury | Oct 27, 2014
Company News

Bavarian Nordic, J&J deal

Bavarian Nordic granted the Johnson & Johnson's Crucell Holland B.V. exclusive, worldwide rights to Ebola vaccine MVA-BN Filo . Bavarian Nordic will receive an upfront payment of $25 million and is eligible to up to $20...
BioCentury | Oct 23, 2014
Company News

Bavarian Nordic gains on J&J Ebola deal

Bavarian Nordic A/S (CSE:BAVA) gained DKK36.50 (24%) to DKK186.50 after the Crucell Holland B.V. unit of Johnson & Johnson (NYSE:JNJ) paid $25 million up front to license exclusive, worldwide rights to Ebola vaccine MVA-BN Filo...
BioCentury | Oct 7, 2013
Company News

CureVac, J&J deal

Johnson & Johnson's Crucell Holland B.V. partnered with CureVac to develop an influenza vaccine. The flu vaccine will use J&J's antigen sequences and CureVac's RNActive technology, which includes optimizing mRNA base-pair content, engineering untranslated regions...
BioCentury | Jan 7, 2013
Company News

GlycoVaxyn, J&J deal

GlycoVaxyn and the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson will use GlycoVaxyn's bio-conjugation technology to develop a multivalent bacterial vaccine. Under the three-year deal, GlycoVaxyn and Janssen's Crucell Holland B.V. affiliate will collaborate...
BioCentury | Jan 5, 2013
Company News

GlycoVaxyn, Janssen in vaccine deal

...bio-conjugation technology to develop a multivalent bacterial vaccine. Under the three-year deal, GlycoVaxyn and Janssen's Crucell Holland BV...
Items per page:
1 - 8 of 8